These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 17701721)

  • 41. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
    Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
    de Mendoza C; Garrido C; Corral A; Zahonero N; Soriano V
    AIDS; 2008 Jan; 22(2):311-3. PubMed ID: 18097236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.
    Pellegrin I; Breilh D; Coureau G; Boucher S; Neau D; Merel P; Lacoste D; Fleury H; Saux MC; Pellegrin JL; Lazaro E; Dabis F; Thiébaut R;
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1473-80. PubMed ID: 17296739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
    Lambert-Niclot S; Masquelier B; Cohen Codar I; Soulie C; Delaugerre C; Morand-Joubert L; Charpentier C; Ferre V; Plantier JC; Montes B; Carret S; Perrot V; Peytavin G; Costagliola D; Calvez V; Marcelin AG;
    J Antimicrob Chemother; 2012 Oct; 67(10):2487-93. PubMed ID: 22733652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study.
    Masquelier B; Costagliola D; Schmuck A; Cottalorda J; Schneider V; Izopet J; Calvez V; Descamps D; Poggi C; Brun-Vézinet F;
    J Med Virol; 2005 Aug; 76(4):441-6. PubMed ID: 15977249
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.
    Kaplan SS; Hicks CB
    J Antimicrob Chemother; 2005 Aug; 56(2):273-6. PubMed ID: 15994247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results.
    Raguin G; Poizat G; Morand-Joubert L; Taburet AM; Le Tiec C; Clavel F; Chêne G; Girard PM;
    AIDS; 2007 Jan; 21(2):241-3. PubMed ID: 17197818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital.
    Smith CJ; Phillips AN; Youle MS; Sabin CA; Lampe FC; Tsintas R; Tyrer M; Johnson MA
    HIV Med; 2007 Jan; 8(1):55-63. PubMed ID: 17305933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
    Valer L; de Mendoza C; Soriano V
    J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.
    Kempf DJ; Isaacson JD; King MS; Brun SC; Xu Y; Real K; Bernstein BM; Japour AJ; Sun E; Rode RA
    J Virol; 2001 Aug; 75(16):7462-9. PubMed ID: 11462018
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.
    Fournier S; Chaffaut C; Maillard A; Loze B; Lascoux C; Gérard L; Timsit J; David F; Bergmann JF; Oksenhendler E; Sereni D; Chevret S; Molina JM
    HIV Med; 2005 Mar; 6(2):129-34. PubMed ID: 15807719
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.
    Rodés B; Sheldon J; Toro C; Jiménez V; Alvarez MA; Soriano V
    J Antimicrob Chemother; 2006 Apr; 57(4):709-13. PubMed ID: 16464891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
    Youle M
    J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
    Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
    J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems.
    De Luca A; Cozzi-Lepri A; Perno CF; Balotta C; Di Giambenedetto S; Poggio A; Pagano G; Tositti G; Piscopo R; Del Forno A; Chiodo F; Magnani G; d'Arminio Monforte A; ;
    Antivir Ther; 2004 Oct; 9(5):743-52. PubMed ID: 15535412
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
    Keiser PH; Nassar N
    Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?
    Champenois K; Baras A; Choisy P; Ajana F; Melliez H; Bocket L; Yazdanpanah Y
    J Med Virol; 2011 Oct; 83(10):1677-81. PubMed ID: 21755502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.